- Finch Therapeutics Group Inc (NASDAQ:FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees.
- The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold on its new drug application.
- The FDA had asked for additional information about Finch's SARS-CoV-2 donor screening protocols. Due to the hold, the company paused enrollment in the late-stage trial, dubbed PRISM4.
- Finch also paused its chronic hepatitis B program.
- Finch said the restructuring would allow it to direct financial resources to the C. difficile and autism spectrum disorder programs.
- The changes will mean $1.1 million in costs for Finch due to severance payments and other expenses.
- The company said the restructuring would be substantially completed by the end of Q2.
- Finch provided a brief update on the clinical hold of the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection, saying that the company had provided a complete response to the agency and is now awaiting feedback.
- Price Action: FNCH shares are down 0.82% at $3.63 during the market session on the last check Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Finch Therapeutics Cuts 20% Workforce, Realigns Focus On C. Diff, Autism Programs
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks